EDIT-201 / Editas Medicine - LARVOL DELTA

[VIRTUAL] Functional characterization of EDIT-201, a multiplexed CRISPR-Cas12a gene edited healthy donor derived NK cell therapy, reveals increased granzyme B and degranulation supporting improved serial killing capacity (AACR 2021) - "Most significantly, our data demonstrated that EDIT-201 not only discharged GzmB more rapidly than control NK cells, but also the amount of GzmB degranulated is greater as well, confirming that enhanced degranulation is a key mechanism by which EDIT-201 has superior functional capacity relative to control NK cells. Together, these data demonstrate one mechanism by which EDIT-201 demonstrates superior cytotoxicity during in vitro killing of SK-OV-3 tumor targets, and continues to support the advancement of EDIT-201 as a potential novel gene edited NK cell-based treatment for cancer."

Clinical • Oncology • GZMA • GZMB • IL15 • LAMP1 • TGFB1 • TGFBR2

[VIRTUAL] EDIT-201: CRISPR-Cas12a gene editing enhances functional metabolism of natural killer cells and enables tumor cell cytolysis in metabolically stressful conditions that inhibit effector cell function (AACR 2021) - "The increase in SRC likely enables EDIT-201 to meet enhanced energy demands necessary to mediate effector function in metabolically challenging conditions, thus sustaining superior cytotoxic capacity and cytokine production.In summary, our data demonstrate enhanced metabolic function of EDIT-201, resulting in superior cytotoxicity in metabolically unfavorable conditions. These data further support the development of EDIT-201 as a novel cell therapy for cancer."

Oncology • Ovarian Cancer • Solid Tumor • IFNG • TGFB1 • TGFBR2 • TNFA

[VIRTUAL] Preclinical Development of Edit-201, a Multigene Edited Healthy Donor NK Cell with Enhanced Anti-Tumor Function and Superior Serial Killing Activity in an Immunosuppressive Environment (ASH 2020) - "Together, the increased overall effector function of CISH/TGFBR2 DKO primary human NK cells and their ability to serial kill, support their development as a potent allogeneic cell-based medicine for cancer. This potential medicine, termed EDIT-201, is being advanced to clinical study."

Hematological Malignancies • Multiple Myeloma • Oncology • Solid Tumor • IFNG • IL15 • TNFA

[VIRTUAL] Preclinical Development of EDIT-201, a Multiplexed CRISPR-Cas12a Gene Edited Healthy Donor Derived NK Cells Demonstrating Improved Persistence and Resistance to the Tumor Microenvironment (SITC 2020) - "Together, the increased overall effector function of CISH/TGFBR2 DKO primary human NK cells support their development as a potent allogeneic cell-based medicine for cancer. This potential medicine, termed EDIT-201, is being advanced to clinical study."

Tumor microenvironment • Oncology • Ovarian Cancer • Prostate Cancer • Solid Tumor • IFNG • IL15 • IL2 • IL2RA • TNFA

[VIRTUAL] Preclinical Development of EDIT-201, a Multiplexed CRISPR-Cas12a Gene Edited Healthy Donor Derived NK Cells Demonstrating Improved Persistence and Resistance to the Tumor Microenvironment (SITC 2020) - "Together, the increased overall effector function of CISH/TGFBR2 DKO primary human NK cells support their development as a potent allogeneic cell-based medicine for cancer. This potential medicine, termed EDIT-201, is being advanced to clinical study."

Tumor microenvironment • Oncology • Ovarian Cancer • Prostate Cancer • Solid Tumor • IFNG • IL15 • IL2 • IL2RA • TNFA

Editas Medicine Announces Second Quarter 2020 Results and Update (GlobeNewswire) - "Editas Medicine plans to present preclinical data on EDIT-201 at a scientific conference in the second half of 2020. The Company plans to file an IND for EDIT-201 in the second half of 2021."

IND • Preclinical • Oncology • Solid Tumor

Editas Medicine and Azzur Group Announce a Multi-year Agreement for EDIT-301 and EDIT-201 Manufacturing (GlobeNewswire) - "Editas Medicine, Inc...and Azzur Cleanrooms on Demand™....announced the companies have entered a multi-year agreement for current Good Manufacturing Practice (cGMP)-compliant cleanroom space for Editas Medicine in Azzur’s Waltham site. Editas Medicine will utilize the space and Azzur’s services to execute pre-clinical and early-phase clinical manufacturing activities for its cell medicines, including EDIT-301 in development for the treatment of sickle cell disease and beta thalassemia and EDIT-201, a healthy donor natural killer (HDNK) cell medicine, in development for solid tumor cancers."

Licensing / partnership • Oncology • Solid Tumor